Cell membranes targeted unimolecular prodrug for programmatic photodynamic-chemo therapy

Jie Yuan,Rong Peng,Dongdong Su,Xingxing Zhang,Hepeng Zhao,Xiujuan Zhuang,Mei Chen,Xiaobing Zhang,Lin Yuan
DOI: https://doi.org/10.7150/thno.55014
IF: 11.6
2021-01-01
Theranostics
Abstract:<p>Photodynamic therapy (PDT) has emerged as one of the most up-and-coming non-invasive therapeutic modalities for cancer therapy in rencent years. However, its therapeutic effect was still hampered by the short life span, limited diffusion distance and ineluctable depletion of singlet oxygen (<sup>1</sup>O<sub>2</sub>), as well as the hypoxic microenvironment in the tumor tissue. Such problems have limited the application of PDT and appropriate solutions are highly demand.</p><p><b>Methods:</b> Herein, a programmatic treatment strategy is proposed for the development of a smart molecular prodrug (<b>D-bpy</b>), which comprise a two-photon photosensitizer and a hypoxia-activated chemotherapeutic prodrug. A rhodamine dye was designed to connect them and track the drug release by the fluorescent signal generated through azo bond cleavage.</p><p><b>Results:</b> The prodrug (<b>D-bpy</b>) can stay on the cell membrane and enrich at the tumor site. Upon light irradiation, the therapeutic effect was enhanced by a stepwise treatment: (i) direct generation of <sup>1</sup>O<sub>2</sub> on the cell membrane induced membrane destruction and promoted the <b>D-bpy</b> uptake; (ii) deep tumor hypoxia caused by two-photon PDT process further triggered the activation of the chemotherapy prodrug. Both <i>in vitro</i> and <i>in vivo</i> experiments, <b>D-bpy</b> have exhabited excellent tumor treatment effect.</p><p><b>Conclusion:</b> The innovative <b>programmatic</b> treatment strategy provides new strategy for the design of follow-up anticancer drugs.</p>
medicine, research & experimental
What problem does this paper attempt to address?